Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation.

Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation.

Item
http://www.wikidata.org/entity/Q44406753
Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantationLiving-donor liver transplantation and hepatitis CCritical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation.Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus.Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation.Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determiningPlasma cell hepatitis induced by the termination of antiviral therapy for recurrent hepatitis C after living donor liver transplantation.
P2860

Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation.

Item
http://www.wikidata.org/entity/Q44406753
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Limited benefit of biochemical ...... g-donor liver transplantation.
@en
Limited benefit of biochemical ...... g-donor liver transplantation.
@nl
type
label
Limited benefit of biochemical ...... g-donor liver transplantation.
@en
Limited benefit of biochemical ...... g-donor liver transplantation.
@nl
prefLabel
Limited benefit of biochemical ...... g-donor liver transplantation.
@en
Limited benefit of biochemical ...... g-donor liver transplantation.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Limited benefit of biochemical ...... g-donor liver transplantation.
@en
P2093
P304
P31
P356
10.1097/TP.0B013E3181671DF0
P433
P478
P50
P577
P698
P921